Presentation title : Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN trial, preliminary month 9+ results Date : Thursday, September 4, 2025 Presenter : Rajiv ...

Men and women may be affected differently by retinitis pigmentosa, a disease that causes blindness over time. That's ...

Aldeyra Therapeutics received FDA fast track designation for ADX-2191 for the treatment of retinitis pigmentosa, according to ...

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

ADX-2191 is a preservative-free intravitreal formulation of methotrexate designed to treat various rare retinal diseases such as retinitis pigmentosa.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal ...

NEWPORT BEACH, Calif., August 18, 2025--jCyte, Inc. is pleased to announce the first patients have been enrolled and treated ...

In this Healio Video Perspective from the Retina World Congress, Huma Qamar, MD, MPH, of Ocugen, overviews programs for ...

Aldeyra (ALDX) announced that the FDA has granted fast track designation for ADX-2191 for the treatment of retinitis pigmentosa. There is ...

Aldeyra Therapeutics ( ($ALDX) ) has shared an update. On August 19, 2025, Aldeyra Therapeutics announced that the FDA granted Fast Track ...

Retinitis Pigmentosa Market Dublin, June 26, 2025 (GLOBE NEWSWIRE) -- The "Retinitis Pigmentosa Market Opportunities and Strategies to 2034" report has been added to ResearchAndMarkets.com's offering.

This work can be read in the journal PLOS Biology. Retinitis pigmentosa is the most common hereditary retinal disease in humans, with a prevalence of one in every 4,000 people worldwide.